HER2-Low status in luminal breast cancer treated with neoadjuvant chemotherapy – Armando Orlandi
Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on LinkedIn:
“Excited to share our latest retrospective study examining the impact of HER2 expression levels (low vs. score 0) in luminal breast cancer patients receiving neoadjuvant chemotherapy!
Key findings from our analysis of 566 patients:
• 60% of luminal breast cancers were HER2-low (IHC 1+ or 2+ with negative FISH)
• pCR rates: 13.2% in HER2-low vs. 17.7% in HER2-0 tumors (p=0.15)
• A trend toward improved IDFS for HER2-low tumors (p=0.07)
• HER2-low tumors show an additional later peak of recurrence compared to HER2-0
• HER2-low expression appears more stable following NACT than HER2-0 status
Our findings support what other studies have suggested – a potentially paradoxical relationship where HER2-low status may be associated with lower pathological complete response rates but potentially better long-term outcomes in this population.
This work has important implications as new ADCs targeting HER2-low breast cancer are being investigated in early-stage settings!”
Authors: Giovanna Garuf et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023